NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets cut their price target on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Stock Down 1.2 %

NYSE NBY opened at $0.62 on Friday. The company has a market cap of $3.03 million, a price-to-earnings ratio of -0.01 and a beta of 0.65. NovaBay Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $9.08. The business’s fifty day moving average is $0.63 and its 200 day moving average is $0.89.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.